Admissions:
None
Delistings:
On Friday 8th August, Celadon Pharmaceuticals (CEL) left AIM
What’s baking in the oven?
Potential** Initial Public Offerings:***
8th August: MedPal AI, the UK-based digital health and artificial intelligence Company focused on wellness management has released its Schedule One for an intended AIM IPO. The core product is a non-clinical, digital health app that aggregates and monitors users' health metrics and provides wellness guidance.
The Company intends to raise £1.6m at 4p with an anticipated market capitalisation on Admission of approximately £16m, for late August 2025. 24th July: Scotch Corner Designer Village, a newly formed single asset real estate company (to be re-registered as a public limited company) which is developing a retail outlet and leisure destination, announces it may consider an IPO on the newly launched Aquis Real Asset Market (ARAM) of the Aquis Stock Exchange. Timing and deal details TBC
Banquet Buffet****
Adsure Services 25.00p £2.65m (AQSE:ADS)
The holding company for TIAA Limited, a specialist business assurance provider operating across the Housing, Healthcare, Government, Education, Charities, and other sectors, announced its consolidated final results and proposed dividend for the year ended 31 March 2025. Total Revenue increased 7.7% to £10.0m (2024: £9.3m) and there was a 74% increase in profit before taxation to £0.8m (2024: £0.5m). Cash balances were £1.1m as of 31 March 2025 (2024: £1.1m) with a proposed final dividend payment increase of 15.2% to 1.14 pence per share (2024: 0.99 pence) to be paid in September 2025.
Aurrigo International 73.00p £42.29m (AURR.L)
The provider of transport technology solutions provides an update on trading for the half year ended 30 June 2025 and outlook for the remainder of the year. The Company has performed broadly in line with the Board's expectations during the first half and expects to report revenues of £3.5m. However, during Q2, the impact of US tariffs on UK car OEM production volumes became increasingly evident, with volatility and deferrals in customer schedules impacting performance. As a result, revenue for the full year is anticipated to fall significantly below current market expectations with H2 revenues expected to be in line with H1 revenues. EBITDA will also be materially impacted, although cost efficiency measures and the £1m of grant funding will provide some mitigation. Cash at 30 June 2025 stood at £1.8m.
The Company expects to announce results for the half ending 30 June 2025 in September 2025.
Chill Brands Group 2.15p £10.89m (CHLL.L)
The consumer packaged-goods distribution Company provides an update on its operational progress, financial position and future strategy, and announces that the Company's listing has been restored. On 23 May 2025, Chill Brands announced that it had raised a total of £1m through the issue of convertible loan notes (CLNs) and a CLN drawdown facility. Currently, £477,000 of the CLN drawdown facility remains undrawn. In addition, the Company anticipates receiving a material VAT rebate in the coming months resulting from elevated operating costs including certain exceptional costs incurred during 2024. Based on current circumstances and modelling of various scenarios, the Company expects that its existing cash and financing facilities will support its operations into 2026. The Company believes further growth will likely entail further capital requirements.
CleanTech Lithium 6.75p £6.77m (CTL.L)
The exploration and development Company advancing sustainable lithium projects in Chile announces the planned acquisition of additional licences at Laguna Verde and its intention to raise approximately £4.3m at 5 pence per share. The Company has on 8 August 2025 signed a binding sale and purchase agreement in Chile to acquire an additional 30 licences in the Laguna Verde project area from a Chilean family office, Minergy Chile SpA, with completion having occurred subject only to payment of US$0.6m from the Firm Placing proceeds. The net proceeds will be used to fund the initial payments for the Acquisition, the final payments for Laguna Verde, technical work and general working capital.
Coro Energy 0.50p £2.40m (CORO.L)*
The South East Asian renewable energy developer announced that it has conditionally raised aggregate gross proceeds of approximately £32,415.19 pursuant to the WRAP Retail Offer. In total, the Placing and the WRAP Retail Offer have conditionally raised gross proceeds of approximately £1.678m for the Company. The WRAP Retail Offer is also conditional, inter alia, on the shareholder resolution being passed at the general meeting of the Company (due to be held on 14 August 2025) and the Placing Shares and the WRAP Retail Offer Shares being admitted to trading on AIM.
Genedrive 1.13p £7.03m (GDR.L)
The point of care pharmacogenetic testing Company provides an unaudited trading update for the financial year ended 30 June 2025. The Board expects to report a doubling of total income of £1m for FY25 (FY24: £0.5m, FY23: £0.06m), driven by increased sales momentum in H2 FY25 which saw income of £0.65m (H1 FY25 £0.35m). The Company already has current visibility at month two of FY26 for around £0.6m of total income in the current financial year. The Company's cash balances are currently £700k and the Board and its advisers continue to actively assess a broad range of financing options for the Company in order to provide additional working capital.
Kromek Group 5.00p £32.75m (KMK.L)
The global detection Company announced that it has received a new biosecurity award from the UK Ministry of Defence as well as other orders in the CBRN Detection segment worth a total of c. £860k, with the majority to be delivered during the first half of the Group's current financial year to 30 April 2026.
Naked Wines 75.40p £55.80m (WINE.L)
The online wine retailer announced the launch of a share buyback programme to purchase ordinary shares of 7.5 pence each in the capital of the Group up to a maximum aggregate consideration of £2m in order to further enhance shareholder returns. All ordinary shares repurchased by the Group under the Share Buyback Programme will be cancelled.
Valereum 3.15p £7.22m (AQSE: VLRM)
The Company focused on the tokenisation of digital and real-world assets announced a £0.6m investment in Metrikus Software, a software company that is pioneering real-time building intelligence and smart infrastructure. This Investment forms part of Valereum's wider strategy of supporting high-growth, data-rich businesses with scalable tokenisation opportunities and its previously announced strategy to increase its exposure to the global real estate ecosystem when investing in DigiShares.
Versarien 0.02p £1.14m (VRS.L)
The advanced engineering materials group provides a further update on its restructuring process and financial position. Whilst the Company continues dialogue with a strategic investor with a view to the investment being completed and continues to market Total Carbide Limited for sale, there is no certainty that either transaction will be successfully concluded in a timeframe that will enable the Company to continue trading. The Board has therefore, in line with its previously indicated intention, appointed Leonard Curtis to conduct an accelerated sale process of the remaining Group assets. In the event that asset sales are required to be concluded it is likely that the maximum proceeds that may be realisable from the sale of the Group's remaining assets will be less than the liabilities of the Group. In these circumstances, the Company would cease trading and would be placed into administration which would result in the suspension of trading of the Company's shares on AIM.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
